First Study Evaluating the Safety and Dosage of YG-01 in Patients With Glioblastoma
YGION Biomedical GmbH is advancing YG-01, a personalized neoantigen peptide-based immunotherapy, into a first-in-human Phase 1 dose-escalation study (not yet recruiting) in glioblastoma patients following standard-of-care therapy. The open-label, single-arm design will assess safety, tolerability, feasibility, and immunogenicity across sequential dose cohorts to establish a recommended dose, with exploratory immune-response and clinical-outcome readouts. The signal to watch is whether a neoantigen vaccine can generate measurable immune activity in GBM, a tumor type that has resisted conventional immunotherapy and adds CNS delivery and immune-suppression hurdles.